Advertisement
U.S. markets closed

SELLAS Life Sciences Group, Inc. (SLS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0300+0.0300 (+3.00%)
At close: 04:00PM EST
1.0300 0.00 (0.00%)
After hours: 07:12PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close1.0000
Open1.0100
Bid0.9800 x 3000
Ask1.0500 x 800
Day's Range0.9600 - 1.0700
52 Week Range0.5000 - 1.9100
Volume634,868
Avg. Volume1,050,575
Market Cap44.792M
Beta (5Y Monthly)2.35
PE Ratio (TTM)N/A
EPS (TTM)-1.5200
Earnings DateMar 14, 2024 - Mar 18, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SLS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SELLAS Life Sciences Group, Inc
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more